Available online 29 May 2023

Cannabidiol (CBD) is one of the most important components of the Cannabis sativa plant with delta9-tetrahydrocannabinol (THC). CBD is used both for medical and recreational purposes. It can be of pharmaceutical grade (Epidyolex®), and also self-service purchased in pharmacy, CBD shops and on the internet (non-pharmaceutical). CBD is almost as widespread as it is poorly understood from a pharmacological point of view and particularly in terms of drug interactions. Drug-drug interactions could lead to clinical complications, and we here gather data currently available on pharmacokinetics (PK) drug-drug interactions with CBD through a narrative review. This review shows that several PK drug-drug interactions exist with different class of medications and aims to help clinicians to better know about CBD for their practice as this product is increasingly used.

Agence nationale de sécurité du médicament et des produits de santé

maximal concentration

summary of product characteristics

delta9-tetrahydrocannabinol

maximal time to reach Cmax

uridine diphospho-glucuronosyltransferase

Cannabidiol

Drug-drug interactions

Pharmacokinetics

Pharmacology

© 2023 Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique.